JP2003512474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512474A5 JP2003512474A5 JP2001533153A JP2001533153A JP2003512474A5 JP 2003512474 A5 JP2003512474 A5 JP 2003512474A5 JP 2001533153 A JP2001533153 A JP 2001533153A JP 2001533153 A JP2001533153 A JP 2001533153A JP 2003512474 A5 JP2003512474 A5 JP 2003512474A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- radiation exposure
- neutropenia
- thrombocytopenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 201000006370 kidney failure Diseases 0.000 description 6
- 208000004235 neutropenia Diseases 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006472 autoimmune response Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- CWVMWSZEMZOUPC-JUAXIXHSSA-N (3s,5s,8r,9s,10s,13s,14s,16r)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](Br)C4)=O)[C@@H]4[C@@H]3CC[C@H]21 CWVMWSZEMZOUPC-JUAXIXHSSA-N 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- CXGDRQWRJUSSAR-XKYJBRGQSA-N (3r,5s,8r,9s,10s,13s,14s,16r,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16,17-triol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CC[C@H]21 CXGDRQWRJUSSAR-XKYJBRGQSA-N 0.000 description 1
- CXGDRQWRJUSSAR-KMDKCDOHSA-N (3s,5s,8r,9s,10s,13s,14s,16s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16,17-triol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H]([C@@H](O)C4)O)[C@@H]4[C@@H]3CC[C@H]21 CXGDRQWRJUSSAR-KMDKCDOHSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16145399P | 1999-10-25 | 1999-10-25 | |
| US60/161,453 | 1999-10-25 | ||
| PCT/US2000/026771 WO2001030802A2 (en) | 1999-10-25 | 2000-09-28 | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512474A JP2003512474A (ja) | 2003-04-02 |
| JP2003512474A5 true JP2003512474A5 (enExample) | 2007-11-29 |
Family
ID=22581233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001533153A Pending JP2003512474A (ja) | 1999-10-25 | 2000-09-28 | 血液細胞欠乏症の治療処置 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1223941B1 (enExample) |
| JP (1) | JP2003512474A (enExample) |
| AT (1) | ATE413179T1 (enExample) |
| AU (3) | AU782736B2 (enExample) |
| CA (1) | CA2388939C (enExample) |
| DE (1) | DE60040753D1 (enExample) |
| WO (1) | WO2001030802A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20060079492A1 (en) | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| US20070129282A1 (en) | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
| DE60045751D1 (de) | 1999-09-30 | 2011-04-28 | Harbor Biosciences Inc | Therapeutische Behandlung androgenrezeptorbedingter Leiden |
| US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| AU2002244247B2 (en) * | 2001-03-01 | 2007-12-13 | Harbor Biosciences, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
| JP2006506445A (ja) * | 2002-08-28 | 2006-02-23 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 治療処置の方法 |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| WO2004089304A2 (en) | 2003-04-01 | 2004-10-21 | Hollis-Eden Pharmaceuticals, Inc. | Antiandrogens with marginal agonist activity and methods of use |
| CA2582231A1 (en) * | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| JP4839021B2 (ja) * | 2005-06-10 | 2011-12-14 | 国立大学法人 岡山大学 | 白血球及び／又は造血幹・前駆細胞動員剤 |
| US8486926B2 (en) | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
| US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| KR101545300B1 (ko) | 2008-04-03 | 2015-08-18 | 하버 바이오사이언시즈 인코포레이티드 | 고체 형태의 약제 |
| PL2300489T3 (pl) | 2008-06-06 | 2016-11-30 | Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych | |
| US20110190323A1 (en) | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| KR102100307B1 (ko) * | 2012-03-21 | 2020-04-14 | 다나-파버 캔서 인스티튜트 인크. | 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도 |
| CA2934819A1 (en) | 2013-12-24 | 2015-07-02 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10836788B2 (en) | 2019-02-05 | 2020-11-17 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL99772C (enExample) * | ||||
| US4602008A (en) * | 1984-12-14 | 1986-07-22 | Progenics, Inc. | Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| IL121070A (en) * | 1995-10-12 | 2004-06-20 | Supergen Inc | LIPOSOME FORMULATIONS OF 5beta STEROIDS |
| IL124001A (en) * | 1995-11-13 | 2004-07-25 | Supergen Inc | Composition for administration of steroids |
| GB9708716D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Chronic heart failure |
| CN100398109C (zh) * | 1998-03-06 | 2008-07-02 | 杨伯翰大学 | 甾族化合物衍生的抗生素 |
-
2000
- 2000-09-28 CA CA002388939A patent/CA2388939C/en not_active Expired - Fee Related
- 2000-09-28 WO PCT/US2000/026771 patent/WO2001030802A2/en not_active Ceased
- 2000-09-28 JP JP2001533153A patent/JP2003512474A/ja active Pending
- 2000-09-28 EP EP00970511A patent/EP1223941B1/en not_active Expired - Lifetime
- 2000-09-28 AT AT00970511T patent/ATE413179T1/de not_active IP Right Cessation
- 2000-09-28 AU AU79880/00A patent/AU782736B2/en not_active Ceased
- 2000-09-28 DE DE60040753T patent/DE60040753D1/de not_active Expired - Lifetime
-
2005
- 2005-11-23 AU AU2005237117A patent/AU2005237117B2/en not_active Ceased
-
2008
- 2008-12-04 AU AU2008255138A patent/AU2008255138B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109152756B (zh) | 胆汁淤积性疾病的治疗方法 | |
| JP2023002544A5 (enExample) | ||
| JP2002519434A5 (enExample) | ||
| JP2010059175A (ja) | ６−フルオロウルソデオキシコール酸（６−ｆｕｄｃａ）を含む結腸腺腫または結腸微小腺腫の処置または進行の遅延用医薬組成物 | |
| JP2011517683A5 (enExample) | ||
| JPWO2019107530A1 (ja) | 炎症性腸疾患の治療薬 | |
| WO2002028428A2 (fr) | Composition vaccinale | |
| WO1994022896A1 (fr) | Ameliorant de la cholestase | |
| CN118593690B (zh) | 一种促进子宫内膜损伤修复的蛋白溶液及其应用 | |
| JPWO2013018837A1 (ja) | 左室拡張機能改善剤 | |
| TWI320711B (en) | Cathartic composition | |
| RU95118123A (ru) | Стероиды с 17-спирометилен-лактоновой или -лактольной группой | |
| JPH1036365A5 (enExample) | ||
| WO1999009992A1 (en) | Neovascularization promoters | |
| Unger et al. | Hepatitis B in chronic kidney disease: moving toward effective prevention | |
| JP2005504776A5 (enExample) | ||
| JP2003532737A5 (enExample) | ||
| KR20210076863A (ko) | 니클로사마이드를 포함하는 섬유증의 예방 및 치료용 조성물 | |
| JP2015520759A5 (enExample) | ||
| JP2002539135A5 (enExample) | ||
| WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
| JP2609479B2 (ja) | カリウム排泄剤 | |
| JPH04134030A (ja) | 徐放性モルヒネ直腸投与製剤 | |
| US6710081B1 (en) | Erection insufficiency remedies | |
| JP2843944B2 (ja) | 利胆剤 |